ACTN4: A Promising Drug Target and Biomarker for Parkinson's Disease

Target Name: ACTN4

NCBI ID: G81

ACTN4

ACTN4: A Promising Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of brain cells, leading to motor symptoms such as tremors, rigidity, and difficulty with movement. The most common cause of Parkinson's disease is the neurotransmitter dopamine, which is affected by a deficiency of dopamine-producing neurons in the brain. In addition to dopamine, other neurotransmitters, including serotonin and norepinephrine, can also be affected in Parkinson's disease. One of the main goals of research in Parkinson's disease is to develop new treatments that can increase levels of dopamine in the brain and slow the progression of the disease.

ACTN4: A Potential Drug Target

ACTN4 is a protein that is expressed in the brain and is involved in the regulation of dopamine release. It is a member of the actinin family, which includes several related proteins that are involved in the regulation of intracellular signaling. Studies have shown that ACTN4 is involved in the regulation of dopamine release and that it may play a role in the development of Parkinson's disease.

One of the main reasons for the potential interest in ACTN4 as a drug target is its involvement in the regulation of dopamine release. Parkinson's disease is characterized by the progressive loss of dopamine-producing neurons in the brain, which leads to the deficiency of dopamine. By targeting ACTN4, researchers may be able to increase levels of dopamine in the brain and slow the progression of the disease.

In addition to its potential role in dopamine regulation, ACTN4 has also been shown to be involved in the regulation of other neurotransmitters, including serotonin and norepinephrine. It has been shown to interact with the neurotransmitter receptor GABA, which is involved in the regulation of anxiety and other behaviors.

Actninin-4 (ACTN4) as a drug target

Actninin-4 (ACTN4) has been shown to interact with several other proteins, including GABA, neurotrophins, and dopamine. This suggests that it may play a role in the regulation of intracellular signaling and may be a useful drug target for the treatment of Parkinson's disease.

One of the main potential benefits of targeting ACTN4 is its potential to increase levels of dopamine in the brain. Studies have shown that ACTN4 is involved in the regulation of dopamine release and that its expression is reduced in the brains of people with Parkinson's disease. By increasing ACTN4 levels in the brain, researchers may be able to slow the progression of the disease and improve the symptoms of Parkinson's disease.

Targeting ACTN4 also has the potential to increase levels of other neurotransmitters, such as serotonin and norepinephrine, which may also be involved in the regulation of Parkinson's disease. These neurotransmitters are involved in the regulation of mood, appetite, and other physiological processes, and may be affected by the deficiency of dopamine caused by Parkinson's disease.

Actninin-4 (ACTN4) as a biomarker

In addition to its potential role as a drug target, ACTN4 may also be useful as a biomarker for the diagnosis and monitoring of Parkinson's disease. The progression of Parkinson's disease is often slow and can be difficult to detect, especially in the early stages of the disease. By measuring the levels of ACTN4 in brain tissue or fluids, researchers may be able to monitor the progression of the disease and identify potential therapeutic targets.

In addition to its potential as a drug target and biomarker, ACTN4 is also of interest as a potential therapeutic target for Parkinson's disease. Studies have shown that blocking ACTN4 with small interfering RNA (siRNA) can

Protein Name: Actinin Alpha 4

Functions: F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. This is a bundling protein (Probable). Probably involved in vesicular trafficking via its association with the CART complex. The CART complex is necessary for efficient transferrin receptor recycling but not for EGFR degradation (PubMed:15772161). Involved in tight junction assembly in epithelial cells probably through interaction with MICALL2. Links MICALL2 to the actin cytoskeleton and recruits it to the tight junctions (By similarity). May also function as a transcriptional coactivator, stimulating transcription mediated by the nuclear hormone receptors PPARG and RARA (PubMed:22351778)

The "ACTN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets